Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones. “Throughout the year, we have highlighted our vision for Geron to become a leader...

Click to view original post